All In Biotech

Drug Trial Radar · NCT01256671

DHEA Against Vaginal Atrophy - Safety Study of 12 Months

Last checked: Nov 20, 2026Latest source record: Oct 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

530

Actual

Start

Dec 2010

Primary completion

Jul 2012

Study completion Dec 2012

Sponsor

Lead sponsor
EndoCeutics Inc.Industry
Sponsor type
Industry
First posted
Dec 8, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 40 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase III trial is to assess the long-term safety of intravaginal dehydroepiandrosterone (DHEA) in non-hysterectomized postmenopausal women with vaginal atrophy aged 40 to 75 years.

Conditions

  • Vaginal Atrophy

Interventions

  • DHEADrug

    Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Long-term Safety of Intravaginal Prasterone (DHEA): EndometriumTime frame: Baseline and Week 52 (or discontinuation)
  2. Long-term Safety of Intravaginal Prasterone (DHEA): Serum Steroid LevelsTime frame: Baseline and Week 52

Locations

41 sites in 2 countries. Site status is shown where the registry gives one.

  • EndoCeutics site # 39

    Montgomery, Alabama

  • EndoCeutics site # 14

    Tucson, Arizona

  • EndoCeutics site # 21

    Sacramento, California

  • EndoCeutics site # 30

    San Diego, California

  • EndoCeutics site # 17

    San Diego, California

  • EndoCeutics site # 36

    Denver, Colorado

  • EndoCeutics site # 42

    Milford, Connecticut

  • EndoCeutics site # 07

    Washington D.C., District of Columbia

  • EndoCeutics site # 45

    Boynton Beach, Florida

  • EndoCeutics site # 26

    Jacksonville, Florida

  • EndoCeutics site # 41

    West Palm Beach, Florida

  • EndoCeutics site # 23

    Sandy Springs, Georgia

  • EndoCeutics site # 10

    Meridian, Idaho

  • EndoCeutics site # 27

    Baltimore, Maryland

  • EndoCeutics site # 22

    Kalamazoo, Michigan

  • EndoCeutics site # 25

    Lincoln, Nebraska

  • EndoCeutics site # 24

    Omaha, Nebraska

  • EndoCeutics site # 28

    Moorestown, New Jersey

  • EndoCeutics site # 50

    Neptune City, New Jersey

  • EndoCeutics site # 44

    New Brunswick, New Jersey

  • EndoCeutics site # 19

    New York, New York

  • EndoCeutics site # 16

    Durham, North Carolina

  • EndoCeutics site # 33

    Beachwood, Ohio

  • EndoCeutics site # 05

    Cleveland, Ohio

  • EndoCeutics site # 47

    Cleveland, Ohio

  • EndoCeutics site # 15

    Columbus, Ohio

  • EndoCeutics site # 35

    Pittsburgh, Pennsylvania

  • EndoCeutics site # 09

    West Jordan, Utah

  • EndoCeutics site # 31

    Charlottesville, Virginia

  • EndoCeutics site # 03

    Norfolk, Virginia

  • EndoCeutics site # 38

    Renton, Washington

  • EndoCeutics site # 13

    Calgary, Alberta, Canada

  • EndoCeutics site # 06

    Bathurst, New Brunswick, Canada

  • EndoCeutics site # 04

    Drummondville, Quebec, Canada

  • EndoCeutics site # 34

    Montreal, Quebec, Canada

  • EndoCeutics site # 12

    Montreal, Quebec, Canada

  • EndoCeutics site # 02

    Québec, Quebec, Canada

  • EndoCeutics site # 01

    Québec, Quebec, Canada

  • EndoCeutics site # 18

    Saint Romuald, Quebec, Canada

  • EndoCeutics site # 08

    Shawinigan, Quebec, Canada

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.